Imaging3 Update on Grapefruit Boulevard Investments, Inc. Proposed reverse acquisition of Imaging3, Inc.


GBI Commences Extraction in Their State-of-the-Art Facilities

Burbank, CA, April 04, 2019 (GLOBE NEWSWIRE) --  Imaging3, Inc. (OTCQB:IGNG), (“Imaging3” or the “Company”), a development stage company focused on the introduction of disruptive technologies in the medical imaging industry, is updating its prior announcement regarding the execution of a non-binding letter of intent (“LOI”) to be acquired in a reverse acquisition (the “Acquisition”) by a privately held Los Angeles based cannabis company.

On Thursday, March 28, 2019, GBI commenced operation of its ethanol-based extraction laboratory at GBI’s facilities and commenced processing and manufacturing of cannabis distillate or ‘honey oil.’ This cannabis distillate or ‘honey oil’ is used in a wide variety of cannabis and hemp products, including, but not limited to, e-cigarettes or ‘vapor’ cartridges, cannabis pre-rolls and cannabis infused edibles. GBI’s Chief Executive Officer, Bradley J. Yourist, stated “GBI has achieved a significant milestone on its path to becoming a fully integrated seed to sale cannabis company. Our state-of-the-art, fully-licensed extraction laboratory is in actual operation. We are converting top quality biomass to highest quality distillate in our licensed facility. We will distribute this cannabis distillate under our California state license into the California cannabis product market. Now that we have the proven ability to legally manufacture and distribute this high quality distillate, it only remains to add additional lab units and source additional biomass to grow our revenues. We believe that our reverse acquisition of IGNG will significantly facilitate our ability to quickly obtain the financing necessary to win the race to become the preeminent fully integrated cannabis product company in California, the USA and eventually the world. Such belief is supported by the term sheets we have received from qualified investors and other inquiries we have entertained. We are very pleased that our many months of hard work and careful planning to get our laboratory approved and operational have paid-off remarkably well.”

John Hollister, IGNG’s current CEO stated, “The launch of GBI’s sophisticated state-of-the-art extraction laboratory is irrefutable evidence of their commitment to and ability to execute their plan. It confirms that current IGNG management’s decision to enter into the GBI transaction and thereby afford current IGNG shareholders with the best available opportunity to have their IGNG holdings enhanced while, at the same time, limiting their risks, was a proper one. We look forward to expeditiously moving ahead with the GBI reverse acquisition and in connection with that finalizing drafting of our definitive share exchange agreement.”

Potential investors in IGNG’s common shares are cautioned that there can be no assurances that the reverse acquisition of IGNG by GBI will ever be closed and that even if it is, there can be no assurance that the Company will thereafter be able to obtain the financing necessary to achieve its articulated goals and further that even if such financing is obtained that it will be sufficient for the Company to achieve its ultimate goals.

About Imaging3, Inc.

Imaging3, Inc., founded in 1993, has developed a patented medical imaging technology, called the Dominion SmartScan™, that produces 3D X-ray images, effectively in real time. The SmartScan technology has the potential to allow healthcare professionals to perform diagnostic and therapeutic procedures more quickly and accurately, which may result in higher throughput for the clinicians and fewer safety risks for patients. Imaging3’s technology exposes patients to less harmful radiation than current equivalent imaging technologies such as CT scans. The company believes this will allow scans to be used in many settings where scanning is currently limited by concerns about radiation exposure. The technology also notably allows for reasonably convenient portability, easier installation and use-readiness, and a significantly reduced cost burden suitable for novel settings and for healthcare systems across varied global settings. Imaging3 plans to submit a 510(k) application to FDA during 2019 and or 2020 to gain marketing authorization for initial applications for the SmartScan technology. Visit the company’s website at for detailed information about the company’s technology. Grapefruit Boulevard Investments, Inc. is a cannabis product company which holds California licenses to manufacture and distribute cannabis products. To obtain further information on GBI’s California cannabis licenses and its business plan and operations, please visit GBI’s website at

About GBI

Grapefruit Boulevard Investments, Inc. (“GBI”) is based in Westwood, Los Angeles, California. GBI holds California licenses to both manufacture and distribute cannabis products and is fully compliant with all applicable laws and regulations to operate such business. GBI has its extraction facility located in the Coachillin Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, located on the extension of North Canyon Rd., approximately 10 miles north of the center of Palm Springs. GBI obtained its California licenses in January of 2018 and commenced distribution of cannabis products in June of 2018. GBI’s goal is to become a seed to sale vertically integrated fully compliant cannabis and CBD product Company.

Safe Harbor Statement

Imaging3 cautions you that any statement included in this press release that is not a description of historical facts is a forward-looking statement. Many of these forward-looking statements contain the words "anticipate," "believe," "estimate," "may" "intend," "expect" and similar expressions. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the company and are subject to a number of risks and uncertainties inherent in the Imaging3’s business, including, without limitation: the company may not ever obtain FDA approval for any of its devices; the company may not be able to secure the funds necessary to support its product development plans; and the company may not ever achieve the market success to sustain a profitable business. In addition, there are risks and uncertainties related to economic recession or terrorist actions, competition from much larger imaging companies, technological obsolescence, unexpected costs and delays, potential product liability claims, and many other factors. More detailed information about Imaging3 and the risk factors that may affect the realization of forward-looking statements is set forth in the company’s filings with the Securities and Exchange Commission, including the company’s Annual Report on Form 10-K and its Quarterly Report on Form 10-Q. Such documents may be read free of charge on the SEC’s website at You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Imaging3 undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Investor Relations Contact:
John Hollister
Chief Executive Officer
4919 Noeline Ave., CA 91436
(805) 908-5719